CDK2AP2: A Potential Drug Target and Biomarker for Cyclin-Dependent Kinase 2-Induced Apoptosis

Target Name: CDK2AP2

NCBI ID: G10263

CDK2AP2

CDK2AP2: A Potential Drug Target and Biomarker for Cyclin-Dependent Kinase 2-Induced Apoptosis

Cyclin-dependent kinase 2 (CDK2) is a key regulator of cell cycle progression and has been implicated in various diseases, including cancer, neurodegenerative disorders, and aging. The kinase domain of CDK2 is often targeted by drugs for cancer treatment, but there is a growing interest in exploring its potential as a drug target for non-cancer applications. One such potential target is CDK2-associated protein 2 (CDK2AP2), a protein that can interact with CDK2 and modulate its activity. In this article, we will explore the potential of CDK2AP2 as a drug target and biomarker for CDK2-mediated processes.

CDK2AP2: A Putative Drug Target

CDK2AP2 is a 21-kDa protein that is expressed in various tissues and cell types, including brain, heart, liver, and muscle. It is a key regulator of CDK2 activity and has been shown to play a role in various cellular processes, including cell growth, apoptosis, and autophagy. CDK2AP2 is a scaffold protein that can interact with CDK2 and form a complex, which can then modulate the activity of the kinase.

Several studies have suggested that CDK2AP2 can be a drug target for various diseases, including cancer. For example, some studies have shown that inhibition of CDK2AP2 can lead to increased cell cycle arrest and apoptosis in cancer cells. Additionally, CDK2AP2 has been shown to be involved in the development of neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Therefore, targeting CDK2AP2 may be a promising approach for the development of new treatments for these diseases.

CDK2AP2 as a Biomarker

CDK2AP2 may also be a useful biomarker for some diseases. For example, some studies have shown that increased expression of CDK2AP2 is associated with poor prognosis in cancer patients. Additionally, CDK2AP2 has been shown to be involved in the development of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Therefore, measuring the expression and levels of CDK2AP2 may be a useful biomarker for the diagnosis and prognosis of these disorders.

CDK2AP2 Interacts with Other Proteins

CDK2AP2 is a protein that can interact with several other proteins, including CDK2, p21 (T-cell kinase), p53, and p73. These interactions may have important implications for cellular processes, including cell growth, apoptosis, and autophagy. For example, CDK2AP2 has been shown to form a complex with CDK2 and p21, which can then modulate the activity of the kinase. Additionally, CDK2AP2 has been shown to interact with p53 and p73, which are important regulators of apoptosis.

Conclusion

In conclusion, CDK2AP2 is a protein that can interact with CDK2 and other proteins, and has been shown to play a role in various cellular processes, including cell growth, apoptosis, and autophagy. Its potential as a drug target and biomarker for CDK2-mediated processes makes it an attractive target for research into the development of new treatments for various diseases.

Protein Name: Cyclin Dependent Kinase 2 Associated Protein 2

Functions: Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin (PubMed:33283408). Inhibits cell cycle G1/S phase transition by repressing CDK2 expression and activation; represses CDK2 activation by inhibiting its interaction with cyclin E and A (PubMed:23781148). Plays a role in regulating the self-renewal of embryonic stem cells (ESCs) and in maintaining cell survival during terminal differentiation of ESCs (By similarity). Regulates microtubule organization of metaphase II oocytes (By similarity)

The "CDK2AP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK2AP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets